Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.47 |
| ▸ | AMY2A | P04746 | 3/20 | 0.45 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.41 |
| ▸ | CD69 | Q07108 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.37 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20390714 | 0.97 | LGALS3 (0.49) | LGALS3LGALS8LGALS4AMY2ACHIA | |
| SCHEMBL20390694 | 0.94 | LGALS3 (0.52) | LGALS3LGALS8LGALS4AMY2ACHIA | |
| SCHEMBL23773049 | 0.94 | LGALS3 (0.44) | LGALS3LGALS8LGALS4AMY2ACHIA | |
| SCHEMBL20390678 | 0.91 | LGALS3 (0.46) | LGALS3LGALS8LGALS4AMY2ACHIA | |
| SCHEMBL20390677 | 0.91 | LGALS3 (0.55) | LGALS3LGALS8LGALS4AMY2ACHIA | |
| SCHEMBL29449498 | 0.90 | LGALS3 (0.54) | LGALS3LGALS8LGALS4AMY2ACHIA | |
| SCHEMBL20390692 | 0.90 | LGALS3 (0.51) | LGALS3LGALS8LGALS4CHIACD69 | |
| SCHEMBL20390705 | 0.89 | LGALS3 (0.44) | LGALS3LGALS8LGALS4AMY2ACHIA | |
| SCHEMBL29540924 | 0.89 | LGALS3 (0.58) | LGALS3LGALS8LGALS4AMY2ACHIA | |
| SCHEMBL29737502 | 0.89 | LGALS3 (0.58) | LGALS3LGALS8LGALS4AMY2ACHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227770-A1 | Bacillus Isolates and Uses Thereof | NOVOZYMES BIOAG A/S (DK) | 2023-07-20 | — | — | US | disclosed |
| US-20180201549-A1 | USE OF FUNGAL STRAINS TO SOLUBILIZE PHOSPHATE AND ENHANCE PLANT GROWTH/YIELD | NOVOZYMES BIOAG A/S (DK) | 2018-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227770-A1 | Bacillus Isolates and Uses Thereof | BLVRB, GLB1, SPOUT1 | LGALS3 1418/4885LGALS8 530/4885LGALS4 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.